Company Overview and News

 
MDxHealth Shareholder Transparency Declaration

2018-04-06 globenewswire
HERSTAL, BELGIUM and IRVINE, CA - April 6, 2018 - MDxHealth SA (Euronext Brussels: MDXH) ("MDxHealth" or the "Company"), a world leader in molecular diagnostics for urological cancers, announced that it received on April 4, 2018 the following notification of significant shareholdings in accordance with the Belgian Act of May 2, 2007 on the disclosure of important participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions (the "Belgian Transparency Act").

 
MDxHealth: Déclaration de Transparence d'un Actionnaire

2018-04-06 globenewswire
IRVINE, CA, et HERSTAL (BELGIQUE) - le 6 avril 2018 - MDxHealth SA (Euronext Brussels: MDXH) ("MDxHealth" ou la "Société"), un leader mondial dans les diagnostics moléculaires de cancers urologiques, a annoncé avoir reçu le 4 avril 2018 la notification des participations significatives suivante conformément à la loi du 2 mai 2007 relative à la publicité des participations importantes dans des émetteurs dont les actions sont admises à la négociation sur un marché réglementé et portant des dispositions diverses (la «Loi Belge relative à la Transparence»).

 
MDxHealth Transparantieverklaring voor Aandeelhouders

2018-04-06 globenewswire
HERSTAL, BELGIË en IRVINE, CA, - 6 april 2018 - MDxHealth SA (Euronext Brussels: MDXH) ("MDxHealth" of de "Vennootschap"), een wereldleider in moleculaire diagnostiek voor urologische kankers, heeft bekend gemaakt dat zij op 4 april 2018 de volgende kennisgeving ontving van belangrijke deelnemingen in overeenstemming met de Belgische wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen in emittenten waarvan aandelen zijn toegelaten tot de verhandeling op een gereglementeerde markt en houdende diverse bepalingen (de "Belgische Transparantiewet").

 
MDxHealth (R) : MDxHealth: Déclaration de Transparence d'un Actionnaire

2018-03-29 globenewswire
Communiqué de presse - Information réglementée - 29 mars 2018, 17h45 HEC IRVINE, CA, et HERSTAL (BELGIQUE) - le 29 mars 2018 - MDxHealth SA (Euronext Brussels: MDXH) ("MDxHealth" ou la "Société"), un leader mondial dans les diagnostics moléculaires de cancers urologiques, a annoncé, avoir reçu le 26 mars 2018 la notification suivante conformément à la loi du 2 mai 2007 relative à la publicité des participations importantes dans des émetteurs dont les actions sont admises à la négociation sur un marché réglementé et portant des dispositions diverses.

 
MDxHealth (R): MDxHealth Shareholder Transparency Declaration

2018-03-29 globenewswire
HERSTAL, BELGIUM and IRVINE, CA- March 29, 2018 - MDxHealth SA (Euronext Brussels: MDXH) ("MDxHealth" or the "Company"), a world leader in molecular diagnostics for urological cancers, announced that it received on March 26, 2018 the following notification of significant shareholdings in accordance with the Belgian Act of May 2, 2007 on the disclosure of important participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions.

 
MDxHealth (R): Denominator PR

2018-03-29 globenewswire
IRVINE, CA, and HERSTAL, BELGIUM - 29 March 2018 - MDxHealth SA (Euronext Brussels: MDXH) ("MDxHealth" or the "Company"), a world leader in molecular diagnostics for urological cancers, announces, in accordance with Article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, that in the context of the capital increase that was completed on 26 March 2018 by means of a private placement through an accelerated bookbuilding procedure, its share capital has increased from EUR 39,844,140.

 
MDxHealth (R): Denominator PR

2018-03-29 globenewswire
HERSTAL, BELGIË en IRVINE, CA, - 29 maart 2018 - MDxHealth SA (Euronext Brussels: MDXH) ("MDxHealth" of de "Vennootschap"), een wereldleider in moleculaire diagnostiek voor urologische kankers, maakt, overeenkomstig artikel 15 van de wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen in emittenten waarvan aandelen zijn toegelaten tot de verhandeling op een gereglementeerde markt en houdende diverse bepalingen, bekend dat in de context van de kapitaalverhoging die werd afgesloten op 26 maart 2018 door middel van een private plaatsing via een versnelde bookbuildingprocedure, haar maatschappelijk kapitaal is gestegen van EUR 39.

 
MDxHealth (R) : Denominator PR

2018-03-29 globenewswire
IRVINE, CA, et HERSTAL (BELGIQUE) - le 29 mars 2018 - MDxHealth SA (Euronext Brussels: MDXH) ("MDxHealth" ou la "Société"), un leader mondial dans les diagnostics moléculaires de cancers urologiques, annonce, conformément à l'article 15 de la loi du 2 mai 2007 relative à la publicité des participations importantes dans des émetteurs dont les actions sont admises à la négociation sur un marché réglementé et portant des dispositions diverses, que dans le contexte de l'augmentation de capital clôturée le 26 mars 2018 via un placement privé par le biais d'une procédure de constitution accélérée d'un livre d'ordres, son capital social a augmenté de EUR 39.

 
MDxHealth (R): MDxHealth Successfully Completes a EUR 36 Million (USD 44 million)(1) Capital Increase

2018-03-22 globenewswire
IRVINE, CA, and HERSTAL, BELGIUM - 22 March 2018 - MDxHealth SA (Euronext Brussels: MDXH), a world leader in molecular diagnostics for urological cancers, announces the successful pricing of its capital increase. The Company raised EUR 36 million (USD 44 million)(1) in gross proceeds by means of a private placement of 9,989,881 new shares at an issue price of EUR 3.60 per share through an accelerated bookbuilding.

 
MDxHealth (R) : MDxHealth réalise avec succès une augmentation de capital à hauteur de EUR 36 millions (USD 44 millions)(1)

2018-03-22 globenewswire
IRVINE, CA, et HERSTAL (BELGIQUE) - le 22 mars 2018 - MDxHealth SA (Euronext Brussels: MDXH) un leader mondial dans les diagnostics moléculaires de cancers urologiques, annonce la détermination finale avec succès du montant de son augmentation de capital. La Société a levé avec succès EUR 36 (USD 44 millions) de fonds bruts à travers un placement privé de 9.989.881 nouvelles actions à un prix d'émission de EUR 3,60 par action à travers une procédure de constitution accélérée d'un livre d'ordres.

 
MDxHealth (R) : MDxHealth lance une Augmentation de Capital

2018-03-21 globenewswire
IRVINE, CA, et HERSTAL (BELGIQUE) - le 21 mars 2018 - MDxHealth SA (Euronext Brussels: MDXH) un leader mondial dans les diagnostics moléculaires de cancers urologiques, annonce le lancement d'une augmentation de capital avec l'émission des nouvelles actions ordinaires par le biais d'un placement privé, destiné principalement à un groupe d'investisseurs institutionnels, qualifiés ou professionnels (y inclus des personnes privées, sous réserve des lois, règles et règlements de droit financier applicables), en Belgique et à l'étranger, avec l'intention d'augmenter le capital social de maximum 20%.

 
MDxHealth (R): MDxHealth Launches Capital Increase

2018-03-21 globenewswire
IRVINE, CA, and HERSTAL, BELGIUM - 21 March 2018 - MDxHealth SA (Euronext Brussels: MDXH) a world leader in molecular diagnostics for urological cancers, announces the launch of a capital increase with the offering of new ordinary shares by means of a private placement targeted primarily to a group of institutional, qualified or professional investors (including, subject to applicable securities law, rules and regulations, natural persons) in and outside of Belgium, with the intention to increase the share capital by up to 20%.

 
MDxHealth (R): SelectMDx Liquid Biopsy Test for Prostate Cancer included in the 2018 European Association Urology Guidelines

2018-03-19 globenewswire
HERSTAL, BELGIUM and IRVINE, CA - 07:00 CEST, March 19, 2018 - MDxHealth SA (Euronext Brussels: MDXH.BR), a world leader in molecular diagnostics for urological cancers, announces today that SelectMDx®, the Company's non-invasive 'liquid biopsy' test that helps to identify patients at increased risk of having aggressive prostate cancer, has been included in the 2018 European Association of Urology (EAU) guidelines.

 
MDxHealth (R) : Le test de biopsie liquide SelectMDx® pour le cancer de la prostate est inclus dans les directives 2018 de l'Association Européenne d'Urologie

2018-03-19 globenewswire
HERSTAL, BELGIQUE et IRVINE, CA - 07 :00 CEST, le 19 mars, 2018 - MDxHealth SA (Euronext Bruxelles : MDXH.BR), un leader mondial dans le diagnostic moléculaire de cancers urologiques, annonce aujourd'hui que SelectMDx®, le test de biopsie liquide non-invasif de la Société qui aide à l'identification de patients qui risquent d'avoir un cancer de la prostate agressif, a été inclus dans les directives 2018 de l'Association Européenne d'Urologie (EAU).

 
MDxHealth, Inc. Opens New Service And Research Laboratory In The Netherlands

2017-10-05 devicespace
HERSTAL, BELGIUM - 07:00 CEST, October 5, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced the opening of its new service and research laboratory at the Novio Tech Campus in Nijmegen, the Netherlands.

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...